C16. Innovations in recruiting participants
Tracks
Clinical Research
| Friday, June 14, 2024 |
| 2:45 PM - 3:45 PM |
| Parkside 1 |
Chair & Speakers
Radhika Butala
Manager, Clinical Trials & Research Unit
Northshore Private Hospital, Part of Ramsay Healthcare
Chair: Innovations in recruiting participants
Biography
Radhika is a passionate Clinical Researcher and Site Advocate with over 17 years of experience and expertise from Trial Coordination to Trial Unit establishment. She has diverse clinical trial expertise in interventional and device studies spread across multiple therapeutic areas. She has operational and managerial experience in the public, private, commercial and academic sectors within the clinical research industry and the Australian Healthcare sector. She is passionate about collaborating, educating and championing young people to seek careers in clinical research. In her current role as Manager of Clinical Trials & Research Unit (CTRU) at North Shore Private Hospital, she is establishing a clinical research unit.
Anthony Murray
Director
SciEngage
Digital Engagement With Research Participants, Online Community Building & Diversity.
Abstract
Sourcing volunteers and research participants remains the clinical trial industry's most critical risk factor. New technologies have been able to help sponsors and sites get the most from patient lists. However, there are several evolving techniques that help discover/evidence, reach, engage, attract and screen would-be participants to research projects through digital approaches.
These techniques include:
* Social Listening - a way to frame and contextualise language used by people in online space
* Digital Marketing - involving 3 key channels for directing appropriate messaging quickly and broadly: online advertising, social media and SEO
* Online Community Building - creating online research advocacy hubs and events for patient groups and their networks
Through work done by Australian recruitment agency Opyl, we uncover some of the risks and opportunities innovators, CROs and sites face when de-risking research projects.
These techniques include:
* Social Listening - a way to frame and contextualise language used by people in online space
* Digital Marketing - involving 3 key channels for directing appropriate messaging quickly and broadly: online advertising, social media and SEO
* Online Community Building - creating online research advocacy hubs and events for patient groups and their networks
Through work done by Australian recruitment agency Opyl, we uncover some of the risks and opportunities innovators, CROs and sites face when de-risking research projects.
Biography
Anthony spent over a decade establishing industry intelligence leader GlobalData Healthcare in Asia Pacific before growing Sydney CRO GreenLight Clinical.
After setting up the Ventri Clinical network with the Australian Cardiovascular Alliance (ACvA), he moved to ASX-listed digital agency Opyl Limited. Anthony leads development and growth activities as Opyl support recruitment for health research and clinical trials through intelligent technologies.
In 2023, Anthony co-founded BioNSW, a non-for-profit industry association for the state's Life Sciences community.
Mr Matthew Britland
Consultant
OMICO (CEO, Medwise Consulting)
Clinical Trials and tribulations - recruitment is rare
Abstract
This session will provide an in-depth look at the PrOSPeCT initiative over the past 12 months, highlighting the lessons learned, patient impacts, maturation of the value proposition, and the integration of real-world data. Additionally, we will discuss how programs like PrOSPeCT are bolstering Australia’s position as a premier destination for clinical trials.
PrOSPeCT is Omico’s landmark program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products. Through this initiative we’re opening up new treatment paths across Australia for people with difficult-to-treat cancers, including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastasic cancers.
20,000 patients will receive cutting-edge screening
Through PrOSPeCT, Omico will undertake comprehensive genomic profiling (CGP) of people with cancer and unmet clinical need, to efficiently link them to clinical trials for novel biomarker-dependent treatments.
$135 million of savings in health care costs
It is estimated that PrOSPeCT will result in considerable savings for the healthcare system in terms of avoided health interventions, including medicines, tests and additional hospital costs.
$525 million in new direct investment in locally-based clinical trials
The pro-active screening of cancer patients as part of PrOSPeCT will allow Australia to tap into the global cancer research market – currently valued at more than AUD $130B.
650+ new jobs in 2 years
PrOSPeCT is expected to generate new opportunities for research scientists involved in genomics, clinical trials and diagnostics
How can we find patients for trials rather than trials for patients ? A-PrOSPeCT
PrOSPeCT is Omico’s landmark program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products. Through this initiative we’re opening up new treatment paths across Australia for people with difficult-to-treat cancers, including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastasic cancers.
20,000 patients will receive cutting-edge screening
Through PrOSPeCT, Omico will undertake comprehensive genomic profiling (CGP) of people with cancer and unmet clinical need, to efficiently link them to clinical trials for novel biomarker-dependent treatments.
$135 million of savings in health care costs
It is estimated that PrOSPeCT will result in considerable savings for the healthcare system in terms of avoided health interventions, including medicines, tests and additional hospital costs.
$525 million in new direct investment in locally-based clinical trials
The pro-active screening of cancer patients as part of PrOSPeCT will allow Australia to tap into the global cancer research market – currently valued at more than AUD $130B.
650+ new jobs in 2 years
PrOSPeCT is expected to generate new opportunities for research scientists involved in genomics, clinical trials and diagnostics
How can we find patients for trials rather than trials for patients ? A-PrOSPeCT
Biography
Matt is an experienced medical director with over 25 years experience in clinical, commercial and medical affairs roles. He is the immediate past president of MAPA (Medical Affairs Professionals of Australasia) and is on the Executive Committee of MAPS (Medical Affairs Professionals Society). Matt is the MD of MedWise, a specialist consulting company who focus on medical affairs/communications and patient affairs and under this role consults into OMICO.
